At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Tazemetostat and Prednisolone for B-cell Lymphomas (Phase 1) and 5 related conditions. Completed, enrolled 400 participants across 52 sites in 10 countries.
Detailed Summary
This is an open-label, multicenter, Phase 1/2 study of tazemetostat as a single agent in subjects with advanced solid tumors or with B-cell lymphomas and tazemetostat in combination with prednisolone in subjects with diffuse large B-cell lymphoma (DLBCL).
Study Details
Timeline
Interventions
Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
Patients who received 40 mg/m\^2 prednisolone once daily on Days 1-5 and 15-19 of Cycles 1-4.
Patients who received 100 mg to 1600 mg of tazemetostat, BID, administered in continuous 28-day cycles.